Do High Rheumatoid Factor Levels Impact Response to Certolizumab Pegol in Patients with Inadequately Controlled Rheumatoid Arthritis? A Post Hoc Analysis of a Phase 3b Trial

被引：0

作者：

Smolen, Josef ^{[1
]}

Mikuls, Ted ^{[2
]}

Galloway, James ^{[3
]}

Muller-Ladner, Ulf ^{[4
]}

Curtis, Jeffrey ^{[5
]}

Hashimoto, Motomu ^{[6
]}

Takeuchi, Tsutomu ^{[7
]}

Choy, Ernest ^{[8
]}

Tanaka, Yoshiya ^{[9
]}

Cara, Carlos ^{[10
]}

Lauwerys, Bernard ^{[11
]}

Tilt, Nicola ^{[12
]}

Ufuktepe, Baran ^{[13
]}

Taylor, Peter C. ^{[14
]}

机构：

[1] Med Univ Vienna, Vienna, Austria

[2] Univ Nebraska Med Ctr, Omaha, NE USA

[3] Kings Coll London, Ctr Rheumat Dis, London, England

[4] Justus Liebig Univ Giessen, Bad Nauheim, Germany

[5] Univ Alabama Birmingham, Hoover, AL USA

[6] Osaka Metropolitan Univ, Osaka, Japan

[7] Keio Univ, Dept Internal Med, Tokyo, Japan

[8] Cardiff Univ Sch Med, Cardiff, Wales

[9] Univ Occupat & Environm Hlth, Dept Internal Med, Kitakyushu, Fukuoka, Japan

[10] UCB Pharma, Madrid, Spain

[11] UCB Pharma, Brussels, Belgium

[12] UCB Pharma, Slough, Berks, England

[13] UCB Pharma, Istanbul, Turkiye

[14] Univ Oxford, Oxford, England

来源：

ARTHRITIS & RHEUMATOLOGY | 2024年 / 76卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

0511

引用

页码：1036 / 1039

页数：4

共 50 条

[1] DO HIGH RHEUMATOID FACTOR LEVELS IMPACT RESPONSE TO CERTOLIZUMAB PEGOL IN PATIENTS WITH INADEQUATELY CONTROLLED RHEUMATOID ARTHRITIS? A POST HOC ANALYSIS OF THE PHASE 3B REALISTIC TRIAL
Smolen, J. S.
Mikuls, T.
Galloway, J.
Mueller-Ladner, U.
Curtis, J. R.
Hashimoto, M.
Takeuchi, T.
Choy, E.
Tanaka, Y.
Cara, C.
Lauwerys, B.
Tilt, N.
Ufuktepe, B.
Taylor, P. C.
ANNALS OF THE RHEUMATIC DISEASES, 2024, 83
[2] DO HIGH RHEUMATOID FACTOR TITRES IMPACT RESPONSE TO TUMOUR NECROSIS FACTOR INHIBITORS? COMPARISON OF CERTOLIZUMAB PEGOL AND ADALIMUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS AND HIGH TITRES OF RHEUMATOID FACTOR: A POST HOC ANALYSIS OF A PHASE 4 TRIAL
Smolen, Josef S.
Taylor, Peter C.
Tanaka, Yoshiya
Cara, Carlos
Lauwerys, Bernard
Xavier, Ricardo
Curtis, Jeffrey R.
Mikuls, Ted R.
Weinblatt, Michael
RHEUMATOLOGY, 2024, 63
[3] Do high rheumatoid factor titres impact response to tumour necrosis factor inhibitors? Comparison of certolizumab pegol and adalimumab in patients with rheumatoid arthritis and high titres of rheumatoid factor: a post hoc analysis of a phase 4 trial.
Smolen, Josef S.
Taylor, Peter C.
Tanaka, Yoshiya
Cara, Carlos
Lauwerys, Bernard
Xavier, Ricardo
Curtis, Jeffrey R.
Mikuls, Ted R.
Weinblatt, Michael
RHEUMATOLOGY, 2024, 63
[4] Impact of high rheumatoid factor levels on treatment outcomes with certolizumab pegol and adalimumab in patients with rheumatoid arthritis
Smolen, Josef S.
Taylor, Peter C.
Tanaka, Yoshiya
Takeuchi, Tsutomu
Hashimoto, Motomu
Cara, Carlos
Lauwerys, Bernard
Tilt, Nicola
Ufuktepe, Baran
Xavier, Ricardo M.
Balsa, Alejandro
Curtis, Jeffrey R.
Mikuls, Ted R.
Weinblatt, Michael
RHEUMATOLOGY, 2024, 63 (11) : 3015 - 3024
[5] Efficacy of certolizumab pegol across baseline rheumatoid factor subgroups in patients with rheumatoid arthritis: Post-hoc analysis of clinical trials
Tanaka, Yoshiya
Takeuchi, Tsutomu
Haaland, Derek
Hall, Stephen
Inanc, Nevsun
Li, Zhanguo
Xavier, Ricardo M. M.
Cara, Carlos
Tilt, Nicola
Taylor, Peter C. C.
INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2023, 26 (07) : 1248 - 1259
[6] CERTOLIZUMAB PEGOL IN PATIENTS WITH RHEUMATOID ARTHRITIS: POOLED EFFICACY ANALYSIS OF PHASE 3 CLINICAL TRIALS ACROSS BASELINE RHEUMATOID FACTOR QUARTILES
Tanaka, Y.
Li, Z.
Inanc, N.
Xavier, R.
Tilt, N.
Cara, C.
Saadoun, C.
Takeuchi, T.
ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 267 - 268
[7] Response to: “A somatization comorbidity phenotype impacts response to therapy in rheumatoid arthritis: post hoc results from the certolizumab pegol phase 4 PREDICT trial”
Annelise Madison
Barbara L. Andersen
Ali Ajam
Arthritis Research & Therapy, 21
[8] Response to: "A somatization comorbidity phenotype impacts response to therapy in rheumatoid arthritis: post hoc results from the certolizumab pegol phase 4 PREDICT trial"
Madison, Annelise
Andersen, Barbara L.
Ajam, Ali
ARTHRITIS RESEARCH & THERAPY, 2019, 21 (1)
[9] Post-Hoc Analysis Showing Better Clinical Response With The Loading Dose Of Certolizumab Pegol In Japanese Patients With Active Rheumatoid Arthritis
Takeuchi, Tsutomu
Yamamoto, Kazuhiko
Yamanaka, Hisashi
Ishiguro, Naoki
Tanaka, Yoshiya
Eguchi, Katsumi
Watanabe, Akira
Origasa, Hideki
Kobayashi, Mariko
Shoji, Toshiharu
Miyasaka, Nobuyuki
Koike, Takao
ARTHRITIS AND RHEUMATISM, 2013, 65 : S989 - S989
[10] IMMUNOGENICITY OF CERTOLIZUMAB PEGOL WITHOUT CONCOMITANT METHOTREXATE AND CLINICAL RESPONSE IN RHEUMATOID ARTHRITIS PATIENTS: POST-HOC ANALYSIS OF THE HIKARI STUDY
Takeuchi, T.
Yamamoto, K.
Yamanaka, H.
Ishiguro, N.
Tanaka, Y.
Eguchi, K.
Watanabe, A.
Origasa, H.
Wada, Y.
Shoji, T.
Miyasaka, N.
Koike, T.
ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 440 - 440

← 1 2 3 4 5 →